Vascular Biogenics Ltd (VBLT)

[Valueinvestor12]

VBLT expects to report interim data from the GLOBE trial in Q3-2017, with top-line results from the full dataset expected to be available in early 2018. (change from mid year to 3rd q. Dror said before the later date the better.

VBL Therapeutics (VBLT) today announced new preclinical data indicating that treatment with ofranergene obadenovec (VB-111) augments the anti-tumor activity of a PD-L1 blocker in lung cancer and melanoma models. The data will be presented tomorrow, May 12, in a poster session at the 20th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), taking place in Washington, DC.